Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders

Sponsor
University of Alabama at Birmingham (Other)
Overall Status
Recruiting
CT.gov ID
NCT04061135
Collaborator
(none)
60
1
2
78.9
0.8

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor symptoms, and propose to investigate changes in brain activity while the investigators perform recordings of the surface and deep structures of the brain, in addition to the typical recordings the investigators perform, during routine deep brain stimulation (DBS) surgery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
N/A

Detailed Description

Movement disorders are a prominent cause of disability worldwide. In the United States, it is estimated that more than 4 million people suffer from Parkinson's disease (PD), essential tremor (ET), and dystonia, making them some of the most prevalent of neurologic disorders. Of these, PD is the most common, and is primarily characterized by tremor, rigidity, and bradykinesia. However, though primarily characterized by motor symptoms, many patients also have prominent non-motor features, including depression and cognitive impairment, with deficiencies in processing speed, memory, attention, and learning. Some of the most debilitating cognitive deficiencies include deficits in goal-directed response selection and response inhibition, language, and/or speech difficulties, all of which substantially contribute to reduced quality of life.

Unfortunately, these features of movement disorders are less well-studied and lack effective treatment options, necessitating that new treatments be investigated. Deep brain stimulation (DBS), while a highly effective treatment for the cardinal features of PD, is essentially ineffective for, and can even worsen other cognitive domains, and there are few studies currently investigating how different parameters of DBS may improve these symptoms. In addition, speech abnormalities are common with Parkinson's disease and DBS can sometimes worsen speech problems. These impairments consists primarily of hypophonia, but cognitive deficits can result in actual language disturbance. It is often difficult to know whether the speech problems are related to language processing or articulation (related to the movement disorder). In an effort to begin addressing these questions, we propose to study motor and non-motor symptoms in patients with movement disorders, and to correlate movement and cognition with underlying neural electrophysiology.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
Actual Study Start Date :
Sep 1, 2019
Anticipated Primary Completion Date :
Mar 31, 2025
Anticipated Study Completion Date :
Mar 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

Parkinson's Disease Patients receiving DBS electrodes

Procedure: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.

No Intervention: Control

Control subjects will be non-Parkinson's Disease patients with essential tremor

Outcome Measures

Primary Outcome Measures

  1. Accuracy via Simon Task (% correct) [Baseline]

    In the Simon task, participants are instructed to respond with a right or left button press (Right = Red, Left = Blue) according to how a word is printed on a screen ("RED" or "BLUE"), regardless of the color in which the word is printed. This is a measurement of accuracy (% correct, ranging from 0-100, with higher scores indicating better performance)

  2. Accuracy via Simon Task (% correct) [0-3 months]

    In the Simon task, participants are instructed to respond with a right or left button press (Right = Red, Left = Blue) according to how a word is printed on a screen ("RED" or "BLUE"), regardless of the color in which the word is printed. This is a measurement of accuracy (% correct, ranging from 0-100, with higher scores indicating better performance)

  3. Response times via Simon Task (sec) [Baseline]

    In the Simon task, participants are instructed to respond with a right or left button press according to the word "RIGHT" or "LEFT" that appears on a screen, regardless of where on the screen it actually appears. This is a measurement response times (continuous measure, from 0-4000 milliseconds) between correct and incorrect responses.

  4. Response times via Simon Task (sec) [0-3 months]

    In the Simon task, participants are instructed to respond with a right or left button press according to the word "RIGHT" or "LEFT" that appears on a screen, regardless of where on the screen it actually appears. This is a measurement response times (continuous measure, from 0-4000 milliseconds) between correct and incorrect responses.

  5. Simon Effect on Response times (sec) [Baseline]

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in response times between congruent and incongruent trials

  6. Simon Effect on Response times (sec) [0-3 months]

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in response times between congruent and incongruent trials

  7. Simon Effect on Accuracy (% correct) [Baseline]

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in accuracy between congruent and incongruent trials

  8. Simon Effect on Accuracy (% correct) [0-3 months]

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in accuracy between congruent and incongruent trials

  9. UPDRS 3 motor score (0-108) [Baseline]

    Participants will undergo motor evaluation using the validated United Parkinson's disease Rating Scale (UPDRS) part 3

  10. UPDRS 3 motor score (0-108) [0-3 months]

    Participants will undergo motor evaluation using the validated United Parkinson's disease Rating Scale (UPDRS) part 3

  11. Dementia Rating Scale Score (0-144 points) [Baseline]

    Participants will undergo neuropsychological testing as part of routine care, including the Dementia Rating Scale

  12. Prefrontal power spectral density (microvolt^2/Hertz) [0-3 months]

    Participants will undergo intracranial monitoring during DBS surgery in which a prefrontal strip electrode will be placed, enabling measurement of brain activity.

  13. Subcortical power spectral density (microvolt^2/Hertz) [0-3 months]

    Participants will undergo intracranial monitoring during DBS surgery in which a DBS electrode will be placed, enabling measurement of brain activity at subcortical targets.

  14. Subcortical time-frequency spectrogram [0-3 months]

    Participants will undergo intracranial monitoring during DBS surgery in which a DBS electrode will be placed, enabling measurement of brain activity at subcortical targets.

  15. Prefrontal time-frequency spectrogram [0-3 months]

    Participants will undergo intracranial monitoring during DBS surgery in which a prefrontal strip electrode will be placed, enabling measurement of brain activity.

  16. Cortical-subcortical coherence (no units) [0-3 months]

    Participants will undergo intracranial monitoring during DBS surgery in which a prefrontal strip electrode and DBS electrode will be placed, enabling measurements of connectivity between these structures.

  17. Cortical-subcortical phase slope index (no units) [0-3 months]

    Participants will undergo intracranial monitoring during DBS surgery in which a prefrontal strip electrode and DBS electrode will be placed, enabling measurements of connectivity between these structures.

Secondary Outcome Measures

  1. Accuracy via Simon Task (% correct) [6 months]

    In the Simon task, participants are instructed to respond with a right or left button press (Right = Red, Left = Blue) according to how a word is printed on a screen ("RED" or "BLUE"), regardless of the color in which the word is printed. This is a measurement of accuracy (% correct, ranging from 0-100, with higher scores indicating better performance)

  2. Response times via Simon Task (sec) [6 months]

    In the Simon task, participants are instructed to respond with a right or left button press according to the word "RIGHT" or "LEFT" that appears on a screen, regardless of where on the screen it actually appears. This is a measurement response times (continuous measure, from 0-4000 milliseconds) between correct and incorrect responses.

  3. Simon Effect on Response times (sec) [6 months]

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in response times between congruent and incongruent trials

  4. Simon Effect on Accuracy (% correct) [6 months]

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in accuracy between congruent and incongruent trials

  5. UPDRS 3 motor score (0-108) [6 months]

    Participants will undergo motor evaluation using the validated United Parkinson's disease Rating Scale (UPDRS) part 3

  6. Comparison of hemispheric differences in power spectral density (p-value, parametric two-tailed t-test) [0-3 months]

    We will compare changes in right and left-hemispheric power spectral density

Other Outcome Measures

  1. Correlation of prefrontal power spectra between outpatient EEG and intraoperative ECOG (correlation coefficient) [0-6 months]

    Participants will perform the Simon task during pre- and post-operative study visits. Power spectra will be compared to intraoperative power spectra.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Eligible for DBS surgery based on multi-disciplinary consensus review

  • Have a diagnosis of Parkinson's disease or Essential Tremor

  • A minimum of 18 years of age

  • Willingness to participate in the paradigms described in the protocol

Exclusion Criteria:
  • Inability to provide full and informed consent

  • Are not surgical candidates due to co-morbid conditions or pregnancy

  • Have not undergone an adequate trial of conservative medical management

  • Have a clinical presentation for which DBS surgery is not indicated

  • Are not able to participate in study-related activities

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alabama at Birmingham Birmingham Alabama United States 35233

Sponsors and Collaborators

  • University of Alabama at Birmingham

Investigators

  • Principal Investigator: Nicole Bentley, MD, University of Alabama at Birmingham

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
J. Nicole Bentley, Principle Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT04061135
Other Study ID Numbers:
  • IRB-300003605
First Posted:
Aug 19, 2019
Last Update Posted:
Apr 8, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by J. Nicole Bentley, Principle Investigator, University of Alabama at Birmingham
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 8, 2022